NRC
ABBV icon

New Republic Capital’s AbbVie ABBV Stock Holding History

New Republic Capital’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$990K Sell
3,936
-2,726
-41% -$586K 0.23% 86
2026
Q1 		$1.45M Buy
6,662
+304
+5% +$67.4K 0.49% 42
2025
Q4 		$1.45M Buy
6,358
+2,389
+60% +$544K 0.39% 46
2025
Q3 		$919K Buy
3,969
+93
+2% +$18.9K 0.28% 47
2025
Q2 		$719K Buy
3,876
+62
+2% +$11.5K 0.25% 55
2025
Q1 		$799K Buy
3,814
+120
+3% +$23.3K 0.35% 47
2024
Q4 		$656K Sell
3,694
-23
-0.6% -$4.23K 0.43% 48
2024
Q3 		$734K Buy
3,717
+78
+2% +$14.6K 0.42% 50
2024
Q2 		$624K Buy
3,639
+26
+0.7% +$4.31K 0.31% 62
2024
Q1 		$658K Buy
3,613
+79
+2% +$13.6K 0.42% 53
2023
Q4 		$548K Buy
3,534
+810
+30% +$118K 0.39% 58
2023
Q3 		$406K Sell
2,724
-185
-6% -$27.2K 0.33% 69
2023
Q2 		$392K Sell
2,909
-147
-5% -$21.6K 0.27% 74
2023
Q1 		$487K Buy
3,056
+1,116
+58% +$171K 0.37% 56
2022
Q4 		$314K Buy
+1,940
New +$297K 0.25% 77

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

New Republic Capital's ABBV Position: Q2 2026 in Review

New Republic Capital reduced its AbbVie (ABBV) stake by 41% in Q2 2026, selling an estimated $586K and leaving 3,936 shares worth $990K. The position accounts for 0.23% of the portfolio, ranked #86.

New Republic Capital first reported a position in ABBV in Q4 2022 and has held it in 15 quarters since. The position peaked at $1.45M in Q4 2025. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • New Republic Capital held 3,936 shares of AbbVie worth $990K as of Q2 2026.
  • New Republic Capital sold 2,726 AbbVie shares in Q2 2026, an estimated $586K.
  • AbbVie made up 0.23% of New Republic Capital's portfolio in Q2 2026, its #86 holding.
  • New Republic Capital first reported a position in AbbVie in Q4 2022 and has held it in 15 quarters since.
  • New Republic Capital's AbbVie position peaked at $1.45M in Q4 2025.
  • 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on New Republic Capital's 13F filing for Q2 2026, filed 31 Jul 2026.